

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Park et al.

Attorney Docket No.: BIZBP004X1

Application No.: 10/642,363

Examiner: Not Assigned

Filed: August 14, 2003

Group: Not Assigned

Title: METHOD FOR INHIBITING TUMOR ANGIOGENESIS AND TUMOR GROWTH

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first-class mail on September 19, 2003, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Signed:

Joyce L. Ferreira

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT 37 CFR §§1.56 AND 1.97(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with the Information Disclosure Statement filed on August 8, 2003 by Applicants, Applicants hereby submit the English translations of the Japanese references. Also enclosed are six (6) newly cited references for consideration.

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO 1449 submitted previously and herewith. A copy of each of the newly listed references is also enclosed.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Application No.: 10/642,363

References listed as 5E and 5F on the 1449 (Yoshina et al., Yakugaku Zasshi, Vol. 98(2), pp. 204-209, (1978), and Yoshina et al., Yakugaku Zasshi, Vol. 97(9), pp. 955-961, (1977) are not in the English language, but an English translation thereof is now attached to the copy of the reference submitted herewith.

This Information Disclosure Statement is: (i) filed within three (3) months of the filing date of the above-referenced application, (ii) believed to be filed before the mailing date of a first Office Action on the merits, or (iii) believed to be filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. BIZBP004X1).

Respectfully submitted,

BEYER WEAVER & THOMAS, LLP

Reginald J. Suyat

Registration No. 28,172

P.O. Box 778 Berkeley, CA 94704-0778

Form 1449 (Modified) Atty Docket No. BIZBP004X1 Application No.: 10/642,363 Applicant: Park et al. Filing Date August 14, 2003 Not Assigned

U.S. Patent Documents

Examiner						Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	class	Date
	1A	6,518,294	02/11/03	Teng et al.			01/24/02
	1B	5,574,168	11/12/96	Kuo et al.			05/03/94
	1 C	6,162,819	12/19/00	Schindler et al.			10/05/98

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	lation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
	1D	10-2001-0060054	09/27/01	Republic of Korea			X	
	1E	0254241	07/18/87	EPO			X	
	1F	EP0667345	02/13/95	EPO			X	
	1G	EP1166785	06/19/01	EPO			X	

Other Documents

Examiner						
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication				
	1H	Ko et al., "YC-1 a Novel Activator of Platelet Guanylate Cyclase", Blood,				
		Vol. 84, No. 12, December 15, 1994, pp. 4226-4233				
	1I	Yeo et al., "YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible				
	İ	Factor-1", Journal of the National Cancer Institute", Vol. 95, No. 7, April 2,				
		2003, pp. 516-525				
	1J	Höckel and Vaupel, "Tumor Hypoxia: Definitions and Current Clinical,				
		Biologic, and Molecular Aspects", Journal of National Cancer Institute, Vol.				
		93, No. 4, February 21, 2001, pp. 266-276				
	1K	Dachs and Tozer, "Hypoxia Modulated Gene Expression: Angiogenesis,				
		Metastasis, and Therapeutic Exploitation", European Journal of Cancer, 36,				
		May 2000, pp. 1649-1660				
Examiner		Date Considered				

Atty Docket No. Application No.: BIZBP004X1 10/642,363 Applicant: Park et al. Filing Date Group August 14, 2003 Not Assigned

Other Documents

		Other Documents					
Examiner							
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication					
:	2A	J. Martin Brown, "The Hypoxic Cell: A Target for Selective Cancer Therapy",					
		Eighteenth Bruce F. Cain Memorial Award Lecture, Cancer Research, 59,					
		December 1, 1999, pp. 5863-5870					
	2B	Forsythe et al., "Activation of Vascular Endothelial Growth Factor Gene					
		Transcription by Hypoxia-Inducible Factor 1", Molecular and Cellular					
		Biology, September 1996, pp. 4604-4613					
	2C	Wang and Semenza, "Purification and Characterization of Hypoxia-Inducible					
		Factor 1", The Journal of Biological Chemistry," Vol. 270, No. 3, January 20,					
		1995, pp. 1230-1237					
	2D	Maxwell et al., "The Tumour Suppressor Protein VHL Targets Hypoxia-					
		Inducible Factors for Oxygen-Dependent Proteolysis," Nature, Vol. 399, May					
		20, 1999, pp. 2710-275					
	2E	Ivan et al., "HIFa Targeted for VHL-Mediated Destruction by Proline					
		Hydroxylation: Implications for O ₂ Sensing", Science, Vol. 292, April 20,					
		2001, pp. 464-451					
	2F	Masson et al., "Independent Function of Two Destruction Domains In					
		Hypoxia-Inducible Factor-α Chains Activated by Polyl Hydroxylation,"					
		European Molecular Biology Organization, The EMBO Journal, Vol. 20, No.					
		18, (2001) pp. 5197-5206					
	2G	1					
		O2-Dependent Degradation Domain Via the Ubiquitin-Proteasome Pathway,"					
		<i>Proc. Natl. Acad. Sci USA</i> , Vol. 95, pp. 7987-7992, July 1998					
	2H	Gregg L. Semenza, "HIF-1 and Tumor Progression: Pathophysiology and					
		Therapeutics," Trends in Molecular Medicine, Vol. 8, No. 4, Suppl. (2002),					
		pp. S62-S67					
	2I	Zhong et al., "Overexpression of Hypoxia Inducible Factor 1α in Common					
		Human Cancers and Their Metastases", Cancer Research, Vol. 59, pp. 5830-					
		5835, November 15, 1999					
	2J	Birner et al., "Overexpression of Hypoxia-Inducible Factor-1\alpha Is a Marker For					
		an Unfavorable Prognosis in Early Stage Invasive Cervical Cancer", Cancer					
		Research, Vol. 60, pp. 4693-4696, September 1, 2000					
Examiner		Date Considered					

Atty Docket No. Application No.:
BIZBP004X1 10/642,363

Information Disclosure Applicant:
Statement By Applicant
Park et al.
Filing Date Group
(Use Several Sheets if Necessary)
August 14, 2003 Not Assigned

Other Documents

Examiner							
Initial	No.	Author, Title, Date, Place (e.g	g. Journal) of Publication				
	3A	Maxwell et al., "Hypoxia-Ind	ucible Factor 1 Modulates Gene Expression in				
		Solid Tumors and Influences	Both Angiogenesis and Tumor Growth", Proc.				
		Natl. Acad. Sci. USA, Vol 94, pp. 8104-8109, July 1997 Medical Science					
	3B		xide Independent Activator of Soluble Guanylate				
	1	Cyclase, Inhibits Platelet-Rick	h Thrombosis in Mice", European Journal of				
		Pharmacology, Vol. 320, pp.	161-166, (1997)				
	3C	Galle et al., "Effects of the Sc	oluble Guanylyl Cyclase Activator, YC-1, on				
		Vascular Tone, Cyclic GMP I	Levels and Phosphodiesterase Activity", British				
	<u> </u>	Journal of Pharmacology'', V	⁷ ol. 127, pp. 195-203 (1999)				
	4D	Chun et al., "Inhibitory Effect of YC-1 on the Hypoxic Induction of					
		Erythropoietin and Vascular Endothelial Growth Factor in Hep3B Cells",					
		Biochemical Pharmacology, Vol. 61, pp. 947-954 (2001)					
	5E	Yoshina et al., Yakugaku Zasshi, Vol. 98(2), pp. 204-209, (1978)					
	5F	Yoshina et al., Yakugaku Zasshi, Vol. 97(9), pp. 955-961, (1977)					
	5G	Jaakkola et al., "Targeting of HIF a to the von Hippel Lindau Ubiquitylati					
		Complex by O ₂ -Regulated Prolyl Hydroxylation", Science, Vol. 292, pp. 46-472, April 20, 2001					
Examiner		I	Date Considered				

Form 1449 (Modified)	Atty Docket No. BIZBP004X1	Application No.: 10/642,363
Information Disclosure Statement By Applicant	Applicant: Park et al.	
	Filing Date	Group
(Use Several Sheets if Necessary)	August 14, 2003	Not Assigned

U.S. Patent Documents

Examiner						Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	class	Date
	A	6,610,726	08/26/03	Pillarisetti et al.			12/19/01
	В	6,589,997	07/08/03	Pillarisetti et al.			06/29/01
	C	6,387,942	05/14/02	Teng et al.			06/18/01
	D	6,518,294	02/11/03	Teng et al.			01/24/02
	E	6,162,819	12/19/00	Schindler et al.			10/05/98
<u> </u>	F	2003-0105336-A1	06/05/03	Schindler et al.			09/24,02

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	lation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
	G							
	H					<u> </u>	<u> </u>	
	I						<u> </u>	
	J							

Other Documents

Examiner							
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication					
	K						
{	L						
	M						
Examiner	<u> </u>	Date Considered					